​​Boehringer's Jardiance now gets CDSCO nod for chronic kidney disease

The Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of chronic kidney disease (CKD). This approval allows nephrologists and cardiologists to use Jardiance for eligible CKD patients, reducing hospitalizations and addressing unmet medical needs.
Source: The Economic Times - Category: Consumer Health News Source Type: news